Upcoming Agents for Osteoporosis
|
|
- Aubrey Gilmore
- 5 years ago
- Views:
Transcription
1 Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic University, Melbourne, Australia
2 Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Radius Honorarium for speaking: Amgen, Radius Michael McClung, MD 2017
3 Osteoporosis: Definition and Pathogenesis Definition A disorder due to bone loss that damages skeletal architecture, weakens the skeleton and predisposes a patient to fracture - a combination of low bone mass and damaged microarchitecture Pathogenesis Imbalance in bone remodeling such that rate of resorption exceeds that of formation Images Courtesy of Drs. David Dempster, Roger Zebazi and Sergio Ragi
4 Osteoporosis Drugs FDA Approved Indications 2017 ANTI-REMODELING AGENTS Bisphosphonates Alendronate Risedronate Ibandronate Zoledronic acid Raloxifene Denosumab BONE STIMULATING AGENT Teriparatide
5 Osteoporosis Treatment: Benefits Many of our current drugs are very effective for treating osteoporosis vertebral fracture by 60-70% hip fracture by 40-60% non-vertebral fracture by 20-35% Fracture protection occurs early after treatment starts and persists as long as treatment is taken In general are well tolerated In clinical trials, have been very safe
6 Osteoporosis Treatment: Limitations Real or perceived intolerance Concerns about safety, especially the long-term safety of bisphosphonates Inconvenient or awkward dosing regimens Poor adherence to therapy No agent restores skeletal structure or strength to normal levels i.e., no cure for osteoporosis Expense M McClung. Personal opinion
7 New and Emerging Treatments Anti-remodeling agents Cathepsin K inhibitors Anabolic agents New analogs of PTH Biological activators of bone formation Anti-sclerostin antibody DKK inhibitors
8 Cathepsin K Inhibition
9 Odanacatib Cathepsin K, the major proteolytic enzyme of osteoclasts Odanacatib very specific inhibitor of cathepsin K inhibits bone resorption without decreasing osteoclast number and function thus preserving bone formation in pre-clinical studies, increased endocortical and periosteal bone formation; increased cortical thickness and strength Convenient once weekly oral dosing in clinical studies
10 Cortical Thickness mm Cortical Thickness mm Odanacatib Increases Cortical Thickness and Strength in Femur of OVX Monkeys Proximal Femur # p<0.05 vs VEH Veh p = 0.08 vs VEH # 6 30 ODN, mg/kg Femoral Neck Central Femur *** Increased cortical volumetric BMD (31% vs controls) Increased cortical thickness in the radius (30%) and femur Increased bending strength Veh 6 30 ODN, mg/kg Cusick T et al. J Bone Miner Res. 2012;27:
11 Percent Change vs Placebo Un - Coupling With Odanacatib Odanacatib - CTX Odanacatib P1NP Sustained inhibition of bone resorption markers Transient decrease in bone formation markers Fully reversible Months Adapted from Eisman JA, McClung MR et al. J Bone Miner Res. 2011;26:242 51
12 % Change from Baseline (Mean ± SE) % Change from Baseline (Mean ± SE) Odanacatib: Bone Mineral Density: 5 Years Placebo ODN 50 mg/ Q week Marked and progressive increase in BMD Lumbar Spine Month % Femoral Neck Month 9.8% Full-Analysis-Set Population / LOCF Langdahl et al. J Bone Miner Res 2012 ;27:
13 Cathepsin K Inhibitor: Odanacatib Phase 3: Fracture Risk Reduction In LOFT study of 16,371 patients, odanacatib 50 mg po once weekly significantly reduced fracture risk in women with osteoporosis Relative risk reduction (%), 95% (confidence interval) spine 54% (2.3% vs 7.2%) hip Discontinue therapy47% (0.7% vs 1.2%) non-vertebral * 23% (6.5% vs 8.0%) Discontinue therapy * Time-dependent decrease in non-vertebral fracture risk Increase in BMD in patients previously treated with alendronate Because of unexpected risk of stroke, development was halted in McClung M et al. ASBMR 2014, 2016
14 Abaloparatide
15 Abaloparatide: Synthetic Analogue of Human PTHrP 1-34 hpth 1-34 hpthrp 1-34 Abaloparatide % hpthrp 38% hpthrp Functional optimization of BA058 based on amino acids More selectively binds to R*G PTH receptor than does PTHrP Hattersley R et al. Endocrine Society. OR31-5, 2014
16 Abaloparatide Abaloparatide Phase 3 study (ACTIVE) Compared to teriparatide less activation of bone remodeling than teriparatide somewhat greater increases in BMD Miller PD et al. JAMA 2016;316:722-33
17 Abaloparatide Phase 3 Extension Study (ACTIVE) Total hip BMD Lumbar spine BMD Miller PD et al. JAMA 2016;316:722-33
18 Abaloparatide Phase 3 Extension Study (ACTIVE) Miller PD et al. JAMA 2016;316:722-33
19 Abaloparatide Phase 3 Extension Study (ACTIVExtend) Fracture protection sustained during 6 months of alendronate therapy Cosman F et al. Mayo Clin Proc 2017;92:200-10
20 Abaloparatide Phase 3 Extension Study (ACTIVExtend) Cosman F et al. Mayo Clin Proc 2017;92:200-10
21 Abaloparatide Phase 3 Study (ACTIVE) Adverse events balanced among treatment groups Adverse events of interest Placebo N = 820 (%) Abaloparatide N = 822 (%) Teriparatide N = 818 (%) Back pain 10.0% 8.5% 7.2% Hypercalciuria 9.0% 11.3% 12.5% Hypercalcemia (uncorrected serum calcium) 0.4% 3.4% 6.4% Miller PD et al. JAMA 2016;316:722-33
22 Abaloparatide - Approval April 28: Abaloparatide approved by FDA for treatment of postmenopausal women with osteoporosis and high risk of fracture warning about risk of osteosarcoma (like teriparatide) cumulative use of teriparatide and abaloparatide limited to 2 years in a patient s lifetime
23 Sclerostin Inhibition
24 LRP5/Wnt Signaling in Osteoblasts BMP PTH Mechanical Load Sclerostin LRP5/Wnt β-catenin Dkk1 Altered transcription of several genes Enhanced bone formation
25 Sclerostin Deficiency Sclerosteosis / van Buchem s Increased bone mass throughout skeleton Very low fracture risk Normal due to absence of sclerostin (SOST) - a bone formation inhibitor Heterozygotes have normal phenotype except high bone mass Photo: Janssens and Van Hul. Hum Mol Genet. 2002;11:
26 Sclerostin Antibody Therapy in Rats Rats ovariectomized at age 6 months. Treatment for 5 weeks beginning at 13 months of age 3D µct images of distal femur at end of study Li et al. J Bone Miner Res. 2009;
27 Sclerostin Antibody Increases Cancellous Bone Volume and Bone Formation Cynomolgus monkeys treated for 10 weeks with sclerostin antibody L2 VERTEBRA PROXIMAL TIBIA VEHICLE Scl-AbIV (30 mg/kg) VEHICLE Scl-AbIV (30 mg/kg) E F G H Marked increase in modeling-based bone formation Ominsky MS et al, J Bone Miner Res 2010;25:948-59
28 Romosozumab Humanized IgG2 monoclonal antibody with high specificity for binding sclerostin Administered subcutaneously at dose of 210 mg Q 4 weeks Inhibits sclerostin action Marked but transient increase in bone formation Decreased bone resorption McClung MR et al. N Engl J Med. 2014;370: Cosman F et al. N Engl J Med. 2016;375:
29 Percentage Change From Baseline Romosozumab Phase 2 Study: Bone Mineral Density Placebo ALN TPTD Romosozumab 210 mg QM *P < vs placebo P < vs ALN ʌ P vs TPTD * ʌ Lumbar Spine 11.3% * ʌ * ʌ * Total Hip *P < vs placebo P < vs ALN ʌ P < vs TPTD * ʌ * ʌ 4.1% Month Data are LS means and 95% CIs Month McClung et al. NEJM 2014;370:412-20
30 Percent Change from Baseline Romosozumab Phase 2 Study: Year 3 - BMD Romosozumab Discontinuation: Transition to Denosumab Romosozumab 210 mg QM* Placebo* Placebo Q6M Lumbar Spine Total Hip % % BL BL Month McClung MR et al. ASBMR 2014.
31 Percent Change from Baseline Romosozumab Phase 2 Study: Year 3 - BMD Romosozumab Discontinuation: Transition to Denosumab Romosozumab 210 mg QM* Placebo* Denosumab 60 mg Q6M Placebo Q6M Lumbar Spine Total Hip % % % 7.1% BL BL Month McClung MR et al. ASBMR 2014.
32 Romosozumab: Phase 3 Studies Phase III studies are underway - evaluation of safety will be important FRAME Year 1 Year 2 Year 3 extension ClinicalTrials.gov Identifier: NCT Romosozumab Denosumab Denosumab Placebo Denosumab Denosumab ARCH ClinicalTrials.gov Identifier: NCT Romosozumab Alendronate Alendronate Alendronate
33 Sclerostin Inhibitor: Romosozumab Phase 3: FRAME: Vertebral Fracture Risk Reduction Year 1 ClinicalTrials.gov Identifier: NCT Romosozumab Placebo 7180 postmenopausal women with osteoporosis Average age 71 years T-scores: L spine -2.7 Total hip -2.5 Prior vertebral fracture 18% Prior non-vert fracture 21% FRAX 10 year MOF risk 13.4% Placebo Romosozumab Cosman F et al. N Engl J Med 2016;375:
34 Sclerostin Inhibitor: Romosozumab Phase 3: FRAME: Vertebral Fracture Risk Reduction Year 1 Year 2 ClinicalTrials.gov Identifier: NCT Romosozumab All patients on Placebo denosumab 60 mg Q6M Fracture protection sustained during 12 months of denosumab therapy Year 2: N=25 Year 2: N=5 Placebo Romosozumab Placebo Romosozumab Cosman F et al. N Engl J Med 2016;375:
35 Sclerostin Inhibitor: Romosozumab Phase 3: FRAME: Non-vertebral Fracture Risk Denosumab Geographic disparity in non-vertebral fracture risk and response to treatment. Placebo Romosozumab Cosman F et al. N Engl J Med 2016;375:
36 Sclerostin Inhibitor: Romosozumab Phase 3: FRAME: Clinical Fracture Risk Denosumab Placebo Romosozumab Cosman F et al. N Engl J Med 2016;375:
37 Sclerostin Inhibitor: Romosozumab Phase 3: FRAME: BMD Cosman F et al. N Engl J Med 2016;375:
38 Sclerostin Inhibitor: Romosozumab Phase 3: FRAME: Adverse Events, Year 1 Placebo N = 3576 N (%) Romosozumab N = 3581 N (%) Adverse events 2850 (79.7) 2806 (78.4) Death 23 (0.6) 29 (0.8) Hypocalcemia 0 1 (<0.1) Hypersensitivity 245 (6.9) 242 (6.8) Injection site reactions 104 (2.9) 187 (5.2) ONJ 0 1 (<0.1) Femoral fracture with atypical features 0 1 (<0.1) Hyperostosis 27 (0.8) 19 (0.5) Cosman F et al. N Engl J Med 2016;375:
39 Romosozumab Carcinogenic Potential and Rat Toxicity Study Romosozumab is an anabolic bone forming agent and an activator of canonical Wnt signaling, raising questions about potential carcinogenic risk. Evidence from genetic models of sclerostin deficiency in humans and animals and from chronic toxicity studies in rats and monkeys suggested that romosozumab could pose a low carcinogenic risk to humans. In a rat lifetime study, no romosozumab-related effects on tumor incidence were observed. The findings of the lifetime study and the weight of evidence factors collectively indicate that romosozumab administration would not pose a carcinogenic risk to humans. Chouinard L et al. Regul Toxicol Pharmacol :212-22
40 New Anabolic Therapies: Phase 3 Study Designs Beginning anabolic therapy followed by an anti-remodeling agent will become standard practice ACTIVE - abaloparatide Abaloparatide Alendronate Months Cosman F et al. Mayo Clin Proc 2017;92: FRAME - romosozumab Romosozumab Denosumab Months Cosman F et al. N Engl J Med 2016;375:
41 Where Will New Drugs Fit into Treatment Menu? Abaloparatide Likely occupy the same niche as teriparatide high risk of vertebral fracture failure of anti-remodeling therapy not yet studied in men or patients on glucocorticoids Romosozumab patients at high risk for fracture in need of skeletal reconstruction patients at imminent risk for vertebral fracture, especially those with recent vertebral fracture patients with very low hip BMD in whom anti-remodeling therapy will never achieve a BMD target
42 New Drugs for Osteoporosis: The Future There are no other drugs in late stage (Phase 2 or 3) clinical development Hopefully, the FNIH project and other studies can provide an appropriate surrogate for fractures so that studies with future drugs can be more efficient and less costly Clinical research efforts must turn from developing new drugs and tools to learning how to implement the strategies we have into clinical practice and meaningful clinical outcomes Photo courtesy of Betsy Love McClung, RN, MN
43 Thank you Michael R. McClung, MD, FACP Founding Director Oregon Osteoporosis Center Portland, Oregon, USA
Current Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More information7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation
New Osteoporosis Treatments Disclosures Mary L. Bouxsein, PhD Department of Orthopedic Surgery Harvard Medical School, Boston, MA Advisory Board: Research funding: Merck, Eli Lilly, Radius Merck, Amgen
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationAACE. Osteoporosis Treatment: Then and Now
AACE 25 th Annual Scientific and Clinical Congress Osteoporosis Treatment: Then and Now Orlando, FL May 28, 2016 Michael R. McClung, MD Oregon Osteoporosis Center Portland, Oregon, USA Disclosures I am
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationTREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE. Nelson B. Watts, MD
TREATING OSTEOPOROSIS IN 2018: WHAT'S OLD, WHAT'S NEW, WHAT'S UNPROVEN AND WHAT'S TRUE Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO Honoraria: Amgen, Radius, Shire Consulting
More informationOsteoporosis 2017 Breaking News. Julie L. Carkin, MD The Seattle Arthritis Clinic
Osteoporosis 2017 Breaking News Julie L. Carkin, MD The Seattle Arthritis Clinic 1 Yes, Hopefully & No Anabolic Teriparatide Abaloparatide Romosozumab blosozumab Anti-catabolic Bisphosphonates Denosumab
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationA KL/R / AN A K/O / P O G G
Outline and New Treatments on the Horizon Steven R. Cummings, MD CPMC and UCSF San Francisco Coordinating Center Support from Lilly and Amgen New treatments, new mechanisms of action Cathepsin K inhibition
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationNEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN
NEW HORIZONS IN OSTEOPOROSIS THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. Investigator-initiated grant Merck No non-fda approved recommendations RISK ASSESSMENT
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationHow to treat osteoporosis With what and for how long?
How to treat osteoporosis With what and for how long? Professor Neil Gittoes Consultant Endocrinologist & Honorary Professor Where will we be going? Drug therapies Current Indications Contraindications/unmet
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationReducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians. Please complete the preassessment before the session starts.
Reducing the Risk of Fracture in Postmenopausal Women: Guidance for Family Physicians Please complete the preassessment before the session starts. Sponsorship and Support This educational activity is jointly
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationOsteoporosis Medications: A Case-Based Discussion. Laila S. Tabatabai, MD August 5, 2017
Osteoporosis Medications: A Case-Based Discussion Laila S. Tabatabai, MD August 5, 2017 Disclosures Eli Lilly Radius Objectives Determine which patients with low bone density require treatment, along with
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationTHE GROWING GAP IN OSTEOPOROSIS TREATMENT
THE GROWING GAP IN OSTEOPOROSIS TREATMENT Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. NONE 1 OVERALL CONCLUSIONS There has been remarkable progress in our understanding
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationNew treatments of osteoporosis
HOSTED BY Available online at www.sciencedirect.com ScienceDirect Osteoporosis and Sarcopenia 1 (2015) 4e21 Review article New treatments of osteoporosis http://www.elsevier.com/locate/afos Bente L. Langdahl
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationOsteoporosis - Pathophysiology and diagnosis. Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark
Osteoporosis - Pathophysiology and diagnosis Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark Objective General knowledge about osteoporosis Optimise your protocols
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationEmerging Therapies for Osteoporosis
Review Article Endocrinol Metab 2015;30:429-435 http://dx.doi.org/10.3803/enm.2015.30.4.429 pissn 2093-596X eissn 2093-5978 Emerging Therapies for Osteoporosis Michael R. McClung Oregon Osteoporosis Center,
More informationTREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
TREATMENT OF OSTEOPOROSIS HOLIDAYS OR NO HOLIDAYS? Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Honoraria: Amgen, Merck, Shire Consulting : AbbVie, Amgen, Merck,
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationTherapeutic Updates in the Prevention and Treatment of Osteoporosis
Therapeutic Updates in the Prevention and Treatment of Osteoporosis 2013 Fall Managed Care Forum Las Vegas November 15, 2013 Steven T Harris MD FACP Clinical Professor of Medicine University of California,
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationOsteoporosis in Men. CME Away India & Sri Lanka March 23 - April 7, 2018
Osteoporosis in Men CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright 2017
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationSummary. Treatment. a larger extent than predicted. spine much faster and to. that fracture protection is greater
The Future of Ost eoporosis Care in Research and Practice ACOI Luncheon October 26, 2010 Steven T Harris MD FACP Clinical i l Profess sor of fmedicine i University of California, San Francisco Treatment
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationOsteoporosis for the PCP and consultant COPYRIGHT. Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center
Osteoporosis for the PCP and consultant Harold Rosen, MD Director- Osteoporosis Prevention and Treatment Center Beth Israel Deaconess Medical Center Potential conflicts of interest None GOALS When to screen/treat?
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationOutline. Switching treatment. Evidence from randomized trials. The effects of switching 7/8/2016. When and for whom? Steven Cummings, MD
Outline Switching treatment When and for whom? Steven Cummings, MD Focus on switching from alendronate or risedronate Evidence about the effects of switching on BMD Purposes of switching Symptoms Poor
More informationDISCLOSURES SUNDEEP KHOSLA, M.D.
ADDRESSING PATIENT CONCERNS REGARDING COMPLICATIONS OF ANTIRESORPTIVE THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. NONE 1 OVERALL CONCLUSIONS There has been
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationAnabolic Therapy With Teriparatide Indications Beyond Osteoporosis
Anabolic Therapy With Teriparatide Indications Beyond Osteoporosis Andreas Panagopoulos MD, PhD Upper Limb & Sports Medicine Orthopaedic Surgeon Assistant Professor, University of Patras Outline Teriparatide
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationNew treatment targets in osteoporosis
National University of Athens Greece New treatment targets in osteoporosis Gourzi Vassiliki PhD Candidate Dept. of Pathophysiology School of Medicine Bone remodeling Physiological process < bone tissue
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationNew therapies for osteoporosis. Dr.Shobhana Mohandas.MD.DGO.FICOG. Sun Medical centre, Thrissur, Kerala.
New therapies for osteoporosis Dr.Shobhana Mohandas.MD.DGO.FICOG. Sun Medical centre, Thrissur, Kerala. Osteoclastic resorption Sema 4 D Plexin B1 from osteo TGF-β1, and IGF-1 Osteoblast Migration Osteoblast
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationHealthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C
Healthy Bones: Osteoporosis Management Laurel Short, MSN, FNP-C Disclosure I have no current affiliation or financial interest with any grantor or commercial interests that may have direct interest in
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationTreatment of Osteoporosis: Unmet Needs and Emerging Solutions
J Bone Metab 2018;25(3):133-140 https://doi.org/10.11005/jbm.2018.25.3.133 pissn 2287-6375 eissn 2287-7029 Review Article Treatment of Osteoporosis: Unmet Needs and Emerging Solutions Bente Lomholt Langdahl,
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More information9/29/2016. John P. Bilezikian, M.D. Disclosures: ADVANCES IN BASIC SCIENCE: New Knowledge. Regulatory Molecules Hormone Action
The Therapeutics of Osteoporosis: Application of Bone Science to Clinical Practice John P. Bilezikian, MD Silererg Professor of Medicine Vice-Chair, International Education and Research Department of Medicine
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationBeyond Bisphosphonates: Future Osteoporosis Therapies
Beyond Bisphosphonates: Future Osteoporosis Therapies Clifford Rosen MD rosenc@mmc.org 1 No Conflicts of Interest 2 Outline What s the evidence for bisphosphonates and why not? Clinical trials with bisphosphonatesfracture
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationTYMLOS (abaloparatide)
TYMLOS (abaloparatide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationImaging to Assess Bone Strength and its Determinants
Imaging to Assess Bone Strength and its Determinants Mary L. Bouxsein, PhD Harvard Medical School, Boston, MA UCSF Osteoporosis Course 26 July 212 Consultant / advisor: Amgen, Eli Lilly, Merck Research
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationAACE. Orlando Drug Holidays. Disclosures. Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health
AACE Orlando 2016 Drug Holidays Disclosures Advisory boards: Alexion, Amgen, Lilly, Merck, Radius Health Scientific grants: Alexion, Amgen, Immunodiagnostics, Lilly, Merck, Regeneron, Radius Health, Roche
More informationOptimizing Management of High Risk Osteoporosis
National Experts Illuminate and Debate Optimizing Management of High Risk Osteoporosis Focus on New Mechanisms and Evidence-Based Strategies for Fracture Prevention in High Risk, Postmenopausal Patients
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationNovel advances in the treatment of osteoporosis
British Medical Bulletin, 2016, 119:129 141 doi: 10.1093/bmb/ldw033 Advance Access Publication Date: 24 August 2016 Invited Review Novel advances in the treatment of osteoporosis Christopher K. Y. Chan,
More information11/4/2018. Osteoporosis Update. ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East. No disclosures.
Osteoporosis Update ACP Oregon Chapter November 9 th, 2018 Sarah Hopkins Providence Medical Group Endocrinology East No disclosures. 1 Goals Review screening recommendations and workup of secondary causes
More informationTymlos (abaloparatide)
Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos
More informationOSTEOPOROSIS, OSTEOARTHRITIS AND MUSKOSKELETAL DISEASE: A CALL FOR ACTION
V O L U M E 5 6 N U M B E R 2 J U N E 2 0 1 4 OSTEOPOROSIS, OSTEOARTHRITIS AND MUSKOSKELETAL DISEASE: A CALL FOR ACTION PANMINERVA MED 2014;56:97-114 J. Y., A. NEUPREZ, CH. BEAUDART, F. BUCKINX, J. SLOMIAN,
More informationOsteoporosis. A Silent Killer. David A. Chappell, MD Endocrinology Private Practice Petaluma, California
Osteoporosis A Silent Killer David A. Chappell, MD Endocrinology Private Practice Petaluma, California Relevant Disclosures Speakers Bureau Astra Zeneca Boehringer Ingelheim AACE/ACE Guidelines American
More informationOsteoporosis Case Studies
2019 Endocrine and Diabetes Symposium for Primary Care Providers Osteoporosis Case Studies Joseph B Hawkins, Jr., MD, FACE Assistant Clinical Professor of Medicine, UCSF Founder, Sierra Endocrine Associates
More informationAACE ANNUAL MEETING. Osteoporois and Fractures across the 5 stages of Chronic Kidney Disease. Boston, Mass Paul D. Miller, M.
AACE ANNUAL MEETING Osteoporois and Fractures across the 5 stages of Chronic Kidney Disease Boston, Mass 2018 Paul D. Miller, M.D Medical Director Paul D. Miller, M.D. Disclosures: Amgen (Consultant, Advisory
More information